跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ONIVYDE - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
ONIVYDE
Authorized
STANDARD
ONIVYDE
ipsen biopharmaceuticals canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
11c6b9893d316f09
Company
ipsen biopharmaceuticals canada inc
Type
Standard
Approval Details
Approval Id
11c6b9893d316f09
Drug Approval Canada Name
ONIVYDE
Product Name
ONIVYDE
Status
Marketed
Status Date
2024-07-18
Original Market Date
2017-10-04
Din
02467135
Drug Class
Human
Dosage Form
Suspension
Route Of Administration
Intravenous
Schedule
Prescription
Ahfs
10:00.00
Atc Original
L01CE02 IRINOTECAN
Atc Name
l 01 ce 02
Aig Number
0159330001
Company Name
ipsen biopharmaceuticals canada inc
Company Address
SUITE 500, 5050 Satellite Drive, Mississauga, Ontario, Canada, L4W 0G1
Active Ingredients
IRINOTECAN (IRINOTECAN SUCROSE OCTASULFATE)
4.3 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
11c6b9893d316f09
Type
Standard
Back to Health Canada Approvals